Bevacizumab biosimilar (bevacizumab-awwb) is safe in the treatment of retinopathy of prematurity
No Thumbnail Available
File version
Author(s)
Liu, Cindy Yue‐Ying
Hong, Zixin
Dai, Shuan
Sheth, Shivanand
Shah, Shaheen
Hong, Zixin
Dai, Shuan
Sheth, Shivanand
Shah, Shaheen
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2024
Size
File type(s)
Location
License
Journal Title
Clinical & Experimental Ophthalmology
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
This publication has been entered in Griffith Research Online as an advance online version.
Access the data
Related item(s)
Subject
Ophthalmology and optometry
Persistent link to this record
Citation
Liu, CY; Hong, Z; Dai, S; Sheth, S; Shah, S, Bevacizumab biosimilar (bevacizumab-awwb) is safe in the treatment of retinopathy of prematurity, Clinical & Experimental Ophthalmology, 2024